letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...6364656667686970717273...100101»
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Sex hormones modulate pathogenic processes in experimental traumatic brain injury. (Pubmed Central) -  Mar 20, 2020   
    Here, we subjected male and female C57Bl/6N mice to the controlled cortical impact (CCI) model of TBI and applied pharmacological inhibitors of steroid hormone synthesis, that is, letrozole (LET, inhibiting estradiol synthesis by aromatase) and finasteride (FIN, inhibiting dihydrotestosterone synthesis by 5α-reductase), respectively, starting 72 h prior CCI, and continuing for a further 48 h after CCI...Taken together, our data suggest a sex-specific impact on pathogenic processes in the injured brain after TBI. Sex hormones may thus modulate pathogenic processes in experimental TBI.
  • ||||||||||  letrozole / Generic mfg.
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low-grade serous ovarian cancer (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_1685;    
    Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences. Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences.
  • ||||||||||  letrozole / Generic mfg.
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low-grade serous ovarian cancer (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_1028;    
    Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences. Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences.
  • ||||||||||  letrozole / Generic mfg.
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low-grade serous ovarian cancer (Metro Toronto Convention Centre - Hall E) -  Mar 19, 2020 - Abstract #SGO2020SGO_393;    
    Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences. Maintenance letrozole is a cost-effective strategy in patients with treated LGSC resulting in a clinically relevant improvement in QALY, LY, and decreased number of recurrences.
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal, IO Biomarker:  Therapeutic potential of selenium in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach. (Pubmed Central) -  Mar 18, 2020   
    Selenium treatment of PCOS rats succeeded, comparable to metformin, to greatly improve the PCOS associated endocrine and metabolic phenotypes and histopathological changes, mostly through modulating mitochondrial dynamics, anti-apoptotic action, alleviating oxidative stress and mitochondrial dysfunction. So, selenium could provide a novel therapeutic strategy for PCOS.
  • ||||||||||  letrozole / Generic mfg., everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) -  Mar 18, 2020   
    P2,  N=40, Active, not recruiting, 
    So, selenium could provide a novel therapeutic strategy for PCOS. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  letrozole / Generic mfg.
    New trial:  Novel Therapy for Poor Responders Management (clinicaltrials.gov) -  Mar 16, 2020   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    A Tale of Unexplained Pneumotoxicity: The Dangers of Palbociclib (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_6401;    
    An exhaustive laboratory workup was done in order to exclude other causes that may result in diffuse lung injury, including infection, environmental exposure, and malignancy. This should not deter physicians from using palbociclib as a chemotherapeutic agent in patient with advanced stage breast cancer, as the PALOMA-2 trial has shown that combining palbociclib with letrozole can lead to a median progression free survival of thirteen months in patients who are ER-positive and HER2-negative.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, Journal, Combination therapy:  Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. (Pubmed Central) -  Mar 14, 2020   
    P2, P3
    In PALOMA-3, patients with prior endocrine resistance received fulvestrant plus palbociclib/placebo...With palbociclib plus endocrine therapy, any grade AEs leading to permanent discontinuation over three years occurred in only 8.3% of patients. Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicities with palbociclib plus endocrine therapy, supporting the ongoing investigation of palbociclib plus endocrine therapy in early breast cancer (NCT02513394).
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. (Pubmed Central) -  Mar 13, 2020   
    These results suggest that if exposure to excess androgens during puberty leads to the development of PCOS, reduction of androgen levels during this time may improve reproductive and metabolic phenotypes in women with PCOS. These results also imply that continuous letrozole exposure is required to model PCOS in pubertal female mice since letrozole exerts activational rather than organizational effects during puberty.
  • ||||||||||  sapanisertib (CB-228) / Calithera
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer (clinicaltrials.gov) -  Mar 12, 2020   
    P1b,  N=0, Withdrawn, 
    These results also imply that continuous letrozole exposure is required to model PCOS in pubertal female mice since letrozole exerts activational rather than organizational effects during puberty. N=13 --> 0 | Trial completion date: Dec 2019 --> Jun 2019 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  Avastin (bevacizumab) / Roche, vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg.
    [VIRTUAL] ANALYSIS OF DRUG TREATMENT OF PATIENTS WITH BREAST CANCER IN MOSCOW REGION () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_755;    
    Analysis of drug therapy of patients with breast cancer in Moscow Region demonstrates that the most prescribed type of drug treatment is hormone therapy. This type of therapy was prescribed to 85,4% of total amount of patients with BC.
  • ||||||||||  paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    [VIRTUAL] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2- BREAST CANCER IN ARGENTINA () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_501;    
    The most prescribed first-line CHT was paclitaxel (40%) and doxorubicin (40%)...The most frequent first-line CHT was paclitaxel (33%) and the most frequent ET was anastrozole (46%)...CONCLUSIONS : Treatment patterns for advanced or metastatic breast cancer in Argentina are highly heterogeneous and have experienced substantial changes during the last years. The high CHT use indicates an unmet need for care.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. (Pubmed Central) -  Mar 7, 2020   
    In all, 338 (of 2150 planned) T1-3, N0-3, M0 hormone receptor positive BC patients with body mass index (BMI) ≥24 kg/m receiving adjuvant letrozole were randomized (enrolment ended due to funding loss)...Although loss of funding reduced sample size, we view these hypothesis generating results as compatible with our hypothesis of a potential beneficial effect of a lifestyle intervention on DFS. They provide support for completion of ongoing randomized controlled trials of the effect of lifestyle interventions in BC outcomes.
  • ||||||||||  Reolysin (pelareorep) / Oncolytics, Andrus Reo
    Trial completion date, Trial primary completion date:  AWARE-1: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (clinicaltrials.gov) -  Mar 6, 2020   
    P1,  N=38, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Mar 2020 --> Oct 2020
  • ||||||||||  carotuximab IV (ENV-105) / Kairos Pharma
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer (clinicaltrials.gov) -  Mar 5, 2020   
    P1/2,  N=14, Active, not recruiting, 
    Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Mar 2020 --> Oct 2020 Recruiting --> Active, not recruiting | N=35 --> 14 | Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Aug 2020
  • ||||||||||  letrozole / Generic mfg., Enbrel (etanercept) / Pfizer, Amgen
    Journal:  ETA-mediated anti-TNF-α therapy ameliorates the phenotype of PCOS model induced by letrozole. (Pubmed Central) -  Feb 26, 2020   
    Furthermore, treatment with TNF-α promoted the production of testosterone in KGN granulosa cells by reducing CYP19A1 expression, whereas ETA treatment blocked this process. In conclusion, anti-TNF-α therapy with ETA may be an efficient method to alleviate PCOS, whose underlying mechanism may be associated with its ability to reduce excessive androgen levels.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Feb 23, 2020   
    P2,  N=29, Recruiting, 
    No abstract available N=59 --> 29
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Ovarian stimulation modalities in poor responders (Pubmed Central) -  Feb 21, 2020   
    N=59 --> 29 Thisreview article presents the encouraging methods applied for POR cases to improve cycle outcome.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Altering rat sexual behavior to teach hormonal regulation of brain imprinting. (Pubmed Central) -  Feb 21, 2020   
    The model involves administering exogenous testosterone to imprint male behavior in female pups or administration of an aromatase inhibitor (letrozole) or an estrogen receptor antagonist (ICI 182,780) to imprint female sexual behavior in male pups...Alteration of mating behavior is evaluated through the numbers of males and females that breed and establish pregnancy. This is a very simple protocol that provides an excellent experiment for student discussion on the effects of hormone action on imprinting brain sexual behavior.